Dazucorilant in Patients With Amyotrophic Lateral Sclerosis (DAZALS)

Status:
Not yet recruiting

Trial end date:
2024-11-01

Target enrollment:

Participant gender:

The purpose of this study is to assess the safety and efficacy of CORT113176 (dazucorilant) in patients with Amyotrophic Lateral Sclerosis (ALS).

Phase 2

Corcept Therapeutics